{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:56:06Z","timestamp":1781661366838,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ygyno.2023.08.007","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T18:19:22Z","timestamp":1693419562000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches"],"prefix":"10.1016","volume":"177","author":[{"given":"Dimitrios","family":"Nasioudis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Llaurado","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Daniel J.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.08.007_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signaling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2023.08.007_bb0010","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signaling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.007_bb0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1947601911408079","article-title":"RAS interaction with PI3K: more than just another effector pathway","volume":"2","author":"Castellano","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ygyno.2023.08.007_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.ygyno.2023.08.007_bb0025","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1158\/1535-7163.MCT-22-0004","article-title":"NOTCH signaling limits the response of low-grade serous ovarian cancers to MEK inhibition","volume":"21","author":"Llaurado Fernandez","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","article-title":"The mitogen-activated protein kinase pathway in melanoma part I \u2013 activation and primary resistance mechanisms to BRAF inhibition","volume":"73","author":"Amaral","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2023.08.007_bb0035","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"22","key":"10.1016\/j.ygyno.2023.08.007_bb0040","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1002\/cncr.28864","article-title":"The MAPK pathway across different malignancies: a new perspective","volume":"120","author":"Burotto","year":"2014","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.007_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1947601911411084","article-title":"Ras in cancer and developmental diseases","volume":"2","author":"Fern\u00e1ndez-Medarde","year":"2011","journal-title":"Genes Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2023.08.007_bb0050","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/ijc.31248","article-title":"KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer","volume":"142","author":"Yang","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.08.007_bb0055","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fonc.2019.01088","article-title":"A comparative analysis of individual RAS mutations in cancer biology","volume":"9","author":"Mu\u00f1oz-Maldonado","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2021.12.021","article-title":"Targeting KRAS G12C mutation in lung adenocarcinoma","volume":"165","author":"Rohatgi","year":"2021","journal-title":"Lung Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2023.08.007_bb0065","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.3390\/cancers13246233","article-title":"Therapeutic targets of KRAS in colorectal cancer","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10324","key":"10.1016\/j.ygyno.2023.08.007_bb0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.ygyno.2023.08.007_bb0080","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-21-0950","article-title":"Tissue-agnostic activity of BRAF plus MEK inhibitor in BRAF V600\u2013mutant tumors","volume":"21","author":"Adashek","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.007_bb0085","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2023.08.007_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2021.08.003","article-title":"MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer","volume":"163","author":"Wu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0100","series-title":"AACR Project GENIE: Powering Precision Medicine Through An International Consortium","author":"The AACR Project GENIE Consortium","year":"2017"},{"key":"10.1016\/j.ygyno.2023.08.007_bb0105","series-title":"OncoKB: A Precision Oncology Knowledge Base JCO Precision Oncology","first-page":"1","volume":"Vol. 1","author":"Chakravarty","year":"2017"},{"key":"10.1016\/j.ygyno.2023.08.007_bb0110","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.ygyno.2023.08.007_bb0115","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook","year":"2021","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.ygyno.2023.08.007_bb0120","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0125","series-title":"ESMO Congress 2021. Abstract LBA6","article-title":"KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or in combination with cetuximab in patients with colorectal cancer harboring a KRAS G12C mutation","author":"Weiss","year":"2021"},{"issue":"13","key":"10.1016\/j.ygyno.2023.08.007_bb0130","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with Sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2023.08.007_bb0135","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0145","doi-asserted-by":"crossref","unstructured":"M.H. Hofmann, D. Gerlach, S. Misale, M. Petronczki, N. Kraut, Expanding the reach of precision oncology by drugging all KRAS mutants, Cancer Discov.Apr 1;12(4):924-937.","DOI":"10.1158\/2159-8290.CD-21-1331"},{"issue":"16_Supplement","key":"10.1016\/j.ygyno.2023.08.007_bb0150","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1538-7445.AM2020-1091","article-title":"Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan","volume":"80","author":"Gerlach","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2023.08.007_bb0155","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-20-2718","article-title":"Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling","volume":"27","author":"Liu","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.ygyno.2023.08.007_bb0160","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ygyno.2023.08.007_bb0165","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00221","article-title":"BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition","volume":"2","author":"Moujaber","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"32","key":"10.1016\/j.ygyno.2023.08.007_bb0175","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib versus Physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.007_bb0180","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.08.007_bb0185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2015.04.005","article-title":"A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"138","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.007_bb0190","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ygyno.2019.09.024","article-title":"Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: an NRG Oncology\/GOG study","volume":"155","author":"Westin","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.08.007_bb0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2019.05.003","article-title":"Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.007_bb0200","doi-asserted-by":"crossref","first-page":"S728","DOI":"10.1016\/j.annonc.2021.08.1168","article-title":"725 MO phase I study of the combination of the dual RAF\/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: results of efficacy in low grade serous ovarian cancer","volume":"32","author":"Banerjee","year":"2021","journal-title":"Ann. Oncol."},{"issue":"Suppl. 16","key":"10.1016\/j.ygyno.2023.08.007_bb0205","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","article-title":"Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766) \u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"41","author":"Banerjee","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.08.007_bb0210","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1158\/1535-7163.MCT-18-0413","article-title":"Combined MEK and BCL-2\/XL inhibition is effective in high-grade serous ovarian Cancer patient-derived xenograft models and BIM levels are predictive of responsiveness","volume":"18","author":"Iavarone","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"392","key":"10.1016\/j.ygyno.2023.08.007_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"22","key":"10.1016\/j.ygyno.2023.08.007_bb0220","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1158\/1078-0432.CCR-18-0494","article-title":"Phase Ib study of binimetinib with paclitaxel in patients with platinum-resistant ovarian cancer: final results, potential biomarkers, and extreme responders","volume":"24","author":"Grisham","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2023.08.007_bb0225","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ygyno.2023.08.007_bb0230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1158\/1535-7163.MCT-20-0002","article-title":"AZD0364 is a potent and selective ERK1\/2 inhibitor that enhances anti-tumor activity in KRAS-mutant tumor models when combined with the MEK inhibitor","volume":"20","author":"Flemington","year":"2021","journal-title":"Selumetinib. Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.ygyno.2023.08.007_bb0235","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/1878-0261.12050","article-title":"NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics","volume":"11","author":"Cirenajwis","year":"2017","journal-title":"Mol. Oncol."},{"issue":"7553","key":"10.1016\/j.ygyno.2023.08.007_bb0240","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.ygyno.2023.08.007_bb0245","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1593\/neo.08784","article-title":"Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations","volume":"10","author":"Sangha","year":"2008","journal-title":"Neoplasia"},{"issue":"8","key":"10.1016\/j.ygyno.2023.08.007_bb0250","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1541-7786.MCR-18-1332","article-title":"Intrinsic resistance to MEK inhibition through BET protein-mediated Kinome reprogramming in NF1-deficient ovarian cancer","volume":"17","author":"Kurimchak","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"23","key":"10.1016\/j.ygyno.2023.08.007_bb0255","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2023.08.007_bb0260","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/s41467-021-24562-2","article-title":"Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting","volume":"12","author":"Bear","year":"2021","journal-title":"Nat. Commun."},{"issue":"57","key":"10.1016\/j.ygyno.2023.08.007_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific antibodies targeting mutant RAS neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci. Immunol."},{"issue":"7659","key":"10.1016\/j.ygyno.2023.08.007_bb0270","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2023.08.007_bb0275","doi-asserted-by":"crossref","first-page":"TPS4672","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4672","article-title":"A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT)","volume":"38","author":"Varghese","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2023.08.007_bb0280","doi-asserted-by":"crossref","first-page":"12142","DOI":"10.3390\/ijms222212142","article-title":"Small-molecule inhibitors and degraders targeting KRAS-driven cancers","volume":"22","author":"Hyun","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:05:16Z","timestamp":1758773116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823014361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":56,"alternative-id":["S0090825823014361"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.08.007","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}